BCL2L1 and cancer: Notably, several senolytic compounds aiming to restore apoptotic mechanisms via BCL-2, BCL-XL, and BCL-W inhibition in cancer cells are currently undergoing clinical trials, highlighting their potential as adjuvants in cancer management [156].